-- Uranium Royalty (URC.TO, UROY) 周四宣布,已同意以19亿美元(含债务)的价格从Orion Resource Partners和安大略省教师养老金计划管理的基金手中收购Sweetwater Royalties,受此消息提振,该公司股价在纳斯达克盘前交易中上涨6.6%。 这家总部位于温哥华的公司表示,将把注册地迁至特拉华州以完成此次交易。Uranium Royalty将保留原有名称,并将此次变更称为“新URC”。现有股东将按1:1的比例获得新URC的股份,而Sweetwater的股东将获得价值8.13亿美元的新公司股份(每股作价3.64美元)和3.3亿美元现金,同时新URC还将承担Sweetwater的6.25亿美元债务。 这项交易将造就美国第二大土地所有者(不包括房地产投资信托基金),以及怀俄明州最大的土地所有者。交易完成后,该公司将控制85万英亩的地表权和450万英亩的矿产开采权,进一步扩大其在萨斯喀彻温省阿萨巴斯卡盆地、怀俄明州和纳米比亚的现有矿产资源组合。该公司表示,此次交易还将使铀矿资源公司(Uranium Royalty)成为美国最大的上市非贵金属矿产资源公司。 此次收购还将使该公司获得Sweetwater在怀俄明州的纯碱矿产资源组合。Sweetwater在怀俄明州已知钠租赁区拥有20万英亩的土地,用于开采这种用于生产玻璃、化学品和其他工业产品的工业矿物。 “我们欢迎这项变革性的合并,它将加速来自位于顶级司法管辖区怀俄明州的具有竞争力、可靠性高且寿命长的资产的近期现金流。我们对怀俄明州有着深厚的感情和熟悉程度。更重要的是,它为我们提供了强大的财务基础,使我们能够在核能历史性增长时期充分实现并扩大我们在铀矿领域的业务。全球铀市场正面临严重的初级供应缺口,预计这将推动未来几年大量的资本投资,”首席执行官斯科特·梅尔比在一份声明中表示。 该公司表示,将以现有现金和4000万美元的认购凭证为此次交易提供资金。 铀矿特许权使用费公司(Uranium Royalty)的股票在盘前交易中上涨0.23美元,至4.15美元。周三在多伦多证券交易所,该股收盘上涨0.25加元,至5.40加元。
Related Articles
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.